PDS Biotechnology Corp
PDSBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How PDSB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Pembrolizumab Monotherapy | Phase 3 | Recurrent Head and Neck Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in PDS Biotechnology Corp's drug pipeline?→
CatalystAlert tracks 1 drug candidate in PDS Biotechnology Corp's (PDSB) pipeline across Phase 3. Its lead program is Pembrolizumab Monotherapy (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PDS Biotechnology Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PDS Biotechnology Corp (PDSB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PDSB biotech catalysts?→
Add PDSB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PDS Biotechnology Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.